Immune progression and plasticity in relation to child age
与儿童年龄相关的免疫进展和可塑性
基本信息
- 批准号:9308334
- 负责人:
- 金额:$ 23.5万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2017
- 资助国家:美国
- 起止时间:2017-03-01 至 2022-02-28
- 项目状态:已结题
- 来源:
- 关键词:5 year oldAdultAgeAllergensAllergicAllergic DiseaseAllergy to peanutsBiologicalChildChildhoodChronicClinicalClinical DataClinical ResearchClinical TrialsCohort AnalysisConsumptionDataDatabasesDiagnosisDisease remissionDoseEmployee StrikesExerciseFoodFood HypersensitivityFosteringGeneral HospitalsGoalsHealthHumanHypersensitivityIgEImmuneImmune systemImmunologicsImmunologyImmunotherapyIndividualIndustryIngestionInterventionIntervention StudiesIntervention TrialLeadershipLifeMassachusettsNational Institute of Allergy and Infectious DiseaseNatural HistoryOralOutcomeParticipantPatientsPhasePhase III Clinical TrialsPhenotypePopulationPopulation StudyPreventionProductionPublishingRandomized Controlled TrialsReactionRecruitment ActivityReportingResearchResearch InfrastructureResearch PersonnelResolutionRiskSamplingSchool-Age PopulationSiteSpontaneous RemissionTestingTherapeuticTimeToddlerTreatment EfficacyWorkage relatedcareerclinical remissionclinically significantcohortdesensitizationfood antigenhigh risk infantindustry partnerinnovationinterestoperationoral immunotherapyprimary outcomeresponseskills
项目摘要
Oral immunotherapy (OIT) for peanut allergy has been the most studied interventional strategy
for children with established allergy and is now the focus of an industry-sponsored phase 3 trial
– one of the first in a field currently lacking any approved therapy. For the majority of patients
treated, they can tolerate OIT adequately and it induces a substantial shift in the dose of
allergen that elicits a reaction to a level well above most accidental ingestions, so long as they
maintain consistent therapeutic exposure. This transient state of clinical protection, or
`desensitization' as it is often referred to by allergists, is deemed an acceptable outcome by
many patients, but there are limitations. For one, when in a desensitized state, unlike someone
who is in true remission, there is some ongoing risk of treatment-associated reactions,
especially with co-factors of inter-current illness, exercise, NSAID use, and others. Secondly,
many patients find it very difficult to adhere to a chronic therapy. Therefore, even without the
goal of ad lib peanut consumption, OIT would be a more beneficial intervention if efficacy were
more durable and easier to maintain after an initial course of treatment. In fact, from several
studies of children from school age and above, about 1/3 of patients do achieve a more durable
benefit from OIT, defined by being able to avoid peanut for a month or more and remaining
clinical tolerant to a clinically significant exposure. Those patients who achieve this more robust
benefit tend to have lower peanut specific IgE levels at baseline, suggesting that there may be
important immunological differences about them, but they are otherwise hard to identify. A just
published study, however, suggests that young age at the time of OIT may also be associated
with persistent tolerance after immunotherapy. This proposal would directly test the hypothesis
that younger patients achieve OIT-induced tolerance at higher rates and would generate the
clinical data and samples necessary to explore the immune mechanisms of age-dependent
disparities.
对花生过敏的口服免疫疗法(OIT)一直是研究毒素的介入策略最多的
对于已建立过敏的儿童,现在是行业赞助的第三阶段试验的重点
- 目前缺乏任何批准疗法的领域中的第一个。大多数患者
经过处理,它们可以充分耐受OIT,并引起剂量的实质转移
只要它们会引起对大多数意外摄入水平的反应,只要它们
保持一致的热暴露。这种短暂的临床保护状态,或
过敏者经常提到的“脱敏”被认为是可以接受的结果
许多患者,但存在局限性。首先,当处于脱敏状态时,与某人不同
真正缓解的人,有一些与治疗相关反应的风险,
尤其是与流行疾病,运动,NSAID使用等的共同因素。第二,
许多患者发现很难遵守慢性疗法。因此,即使没有
AD LIB花生消费的目标,如果生效是有效的,OIT将是更有益的干预
初步治疗后,更耐用,更容易维护。实际上,来自几个
研究年龄及以上儿童的研究,大约有1/3的患者确实达到了更耐用的患者
OIT的益处,通过能够避免花生一个月或更长时间而定义
对临床显着暴露的临床耐受性。那些实现这一更强大的患者
益处在基线时往往具有较低的花生特异性IgE水平,这表明可能存在
它们的重要免疫学差异,但否则它们很难识别。公正
然而,已发表的研究表明,OIT时代的年龄也可能与之相关
免疫疗法后具有持续的耐受性。该建议将直接检验假设
年轻的患者以较高的速率实现OIT诱导的公差,并将产生
探索依赖年龄的免疫机制所需的临床数据和样品
差异。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
WAYNE G SHREFFLER其他文献
WAYNE G SHREFFLER的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('WAYNE G SHREFFLER', 18)}}的其他基金
2020 Food Allergy Gordon Research Conference and Gordon Research Seminar
2020年食物过敏戈登研究会议暨戈登研究研讨会
- 批准号:
9914389 - 财政年份:2019
- 资助金额:
$ 23.5万 - 项目类别:
Immune progression and plasticity in relation to child age
与儿童年龄相关的免疫进展和可塑性
- 批准号:
10416402 - 财政年份:2017
- 资助金额:
$ 23.5万 - 项目类别:
Immune progression and plasticity in relation to child age
与儿童年龄相关的免疫进展和可塑性
- 批准号:
10579324 - 财政年份:2017
- 资助金额:
$ 23.5万 - 项目类别:
Regulatory and effector T cells in oral immunotherapy for food allergy
食物过敏口服免疫疗法中的调节性和效应性 T 细胞
- 批准号:
8196488 - 财政年份:2011
- 资助金额:
$ 23.5万 - 项目类别:
Mechanisms of Clinical Reactivity or Tolerance to Mouse Allergen
对小鼠过敏原的临床反应或耐受机制
- 批准号:
8081806 - 财政年份:2010
- 资助金额:
$ 23.5万 - 项目类别:
Mechanisms of Clinical Reactivity or Tolerance to Mouse Allergen
对小鼠过敏原的临床反应或耐受机制
- 批准号:
7783801 - 财政年份:2010
- 资助金额:
$ 23.5万 - 项目类别:
Mechanisms of Clinical Reactivity or Tolerance to Mouse Allergen
对小鼠过敏原的临床反应或耐受机制
- 批准号:
8470527 - 财政年份:2010
- 资助金额:
$ 23.5万 - 项目类别:
Mechanisms of Clinical Reactivity or Tolerance to Mouse Allergen
对小鼠过敏原的临床反应或耐受机制
- 批准号:
8308660 - 财政年份:2010
- 资助金额:
$ 23.5万 - 项目类别:
Mechanisms of peanut (A. hypogaea) glycan adjuvanticity.
花生(A.hypogaea)聚糖佐剂的机制。
- 批准号:
7919656 - 财政年份:2009
- 资助金额:
$ 23.5万 - 项目类别:
Mechanisms of oral immunotherapy-induced suppression of type I hypersensitivity.
口服免疫疗法诱导抑制 I 型超敏反应的机制。
- 批准号:
8013729 - 财政年份:2008
- 资助金额:
$ 23.5万 - 项目类别:
相似国自然基金
成人型弥漫性胶质瘤患者语言功能可塑性研究
- 批准号:82303926
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
MRI融合多组学特征量化高级别成人型弥漫性脑胶质瘤免疫微环境并预测术后复发风险的研究
- 批准号:82302160
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
成人免疫性血小板减少症(ITP)中血小板因子4(PF4)通过调节CD4+T淋巴细胞糖酵解水平影响Th17/Treg平衡的病理机制研究
- 批准号:82370133
- 批准年份:2023
- 资助金额:49 万元
- 项目类别:面上项目
SMC4/FoxO3a介导的CD38+HLA-DR+CD8+T细胞增殖在成人斯蒂尔病MAS发病中的作用研究
- 批准号:82302025
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
融合多源异构数据应用深度学习预测成人肺部感染病原体研究
- 批准号:82302311
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
相似海外基金
Neonatal Optical Coherence Tomography Angiography to Assess the Effects of Postnatal Exposures on Retinal Development and Predict Neurodevelopmental Outcomes
新生儿光学相干断层扫描血管造影评估产后暴露对视网膜发育的影响并预测神经发育结果
- 批准号:
10588086 - 财政年份:2023
- 资助金额:
$ 23.5万 - 项目类别:
Improving Age- and Cause-Specific Under-Five Mortality Rates (ACSU5MR) by Systematically Accounting Measurement Errors to Inform Child Survival Decision Making in Low Income Countries
通过系统地核算测量误差来改善特定年龄和特定原因的五岁以下死亡率 (ACSU5MR),为低收入国家的儿童生存决策提供信息
- 批准号:
10585388 - 财政年份:2023
- 资助金额:
$ 23.5万 - 项目类别:
Identifying correlates of risk for future tuberculosis disease progression in children (INTREPID)
确定儿童未来结核病进展风险的相关性 (INTREPID)
- 批准号:
10637036 - 财政年份:2023
- 资助金额:
$ 23.5万 - 项目类别:
Effects of age of acquisition and of community on argument ordering
习得年龄和社区对论证顺序的影响
- 批准号:
10825319 - 财政年份:2023
- 资助金额:
$ 23.5万 - 项目类别: